Abstract Body

Background:

Dolutegravir (DTG) is an integrase strand transfer inhibitor, which is currently recommended as part of first-line treatment regimens for HIV-1 patients worldwide. This is particularly due to its high potency, limited drug-drug interactions and intrinsic high genetic barrier to resistance. Nonetheless, concerns emerged for its usage in pregnant women. Notably, DTG-based regimens have been linked to neural tube defects and postnatal neurodevelopmental deficits when taken at conception. To this end, the need for intervention strategies that would maximize DTG’s efficacy benefits while limiting adverse events cannot be overstated. Thus, we created and evaluated an intramuscularly administered long-acting nanoformulated DTG (NDTG). Our goal was to determine whether poloxamer coated NDTG would sustain therapeutic DTG levels in the mother’s peripheral system with minimal drug exposure to the embryo brain during pregnancy.

Methods:

Female C3H/HeJ mice were either treated orally every day with DTG at human therapeutic equivalent dosage (5 mg/kg) starting at gestation day (GD) 0.5, with a single intramuscular (IM) injection of NDTG (45 mg/kg) at GD 0.5 or with two NDTG (25 mg/kg) intramuscular injections, first at GD 0.5 and second at GD 9.5. DTG concentrations were measured in plasma of dams and in whole brain tissues of embryos at GD 16.5 and at GD 17.5, respectively, using mass spectrometry (LC-MS/MS).

Results:

Single (45 mg/kg) or two (25 mg/kg) IM injections of NDTG achieved equivalent plasma DTG levels to daily oral DTG administration (5 mg/kg) in pregnant dams. In all the treatment groups, plasma DTG levels were between 4000-6500 ng/mL, which are comparable to therapeutic DTG concentrations from daily oral dosing in humans. However, significantly lower levels of DTG biodistribution in embryo brain was observed following NDTG injections in comparison to daily oral administration. For daily oral DTG administration, average DTG concentrations of 196 ng/g were recorded in the embryo brains compared to 34 ng/g and 45 ng/g for groups administered with single or two IM injections of NDTG, respectively.

Conclusions:

This work demonstrates that long-acting DTG nanoformulations sustain therapeutic DTG levels in maternal plasma while limiting drug exposure to the embryo brain during pregnancy. Our preliminary work shows that novel drug delivery approaches could potentially minimize embryo brain DTG exposure and thus, potentially limit drug related neurodevelopmental toxicities.

Figure_Emma_Longacting NDTG Poster.tif